When endoscopic therapy or pharmacotherapy fails to control variceal bleeding: what should be done? Immediate control of bleeding by TIPS?
BACKGROUND
Acute variceal bleeding is the major cause of death in patients with chronic liver disease. This justifies the search for a more effective therapy to achieve rapid and definitive hemostasis in every patient. At present, the recommended standard treatment for acute variceal bleeding consists of immediate drug treatment with terlipressin or octreotide together with early endoscopic band ligation or sclerotherapy. In the case of ectopic varices terlipressin and cyanoacrylate embolization (if varices can be reached by endoscope) are in use.


OBJECTIVE
The treatment is considered to have failed when bleeding continues or significant bleeding recurs within 48 h. This indicates the need for emergency transjugular intrahepatic portosystemic shunting (TIPS) which has been regarded as rescue treatment of choice when standard treatment fails. Although randomized studies against supportive treatment are lacking, the high efficacy and relatively low mortality after TIPS implantation are convincing. It is reasonable that smaller shunts should be preferred (probably 8 mm in diameter) since most patients have an increased risk of liver failure. To increase the effect of the shunt with respect to acute hemostasis it should be combined with transjugular embolization of the varices.


CONCLUSIONS
Only strict adherence to the definition of failure of standard treatment and a generous indication to the TIPS implantation before multiorgan failure occurs may decrease the high mortality of acute variceal bleeding.
Praxiszentrum, Bertoldstrasse 48, 79098 Freiburg, Germany. Martin-Roessle@t-online.de
Martin
M
Rössle
D000208:Acute Disease; D003487:Cyanoacrylates / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D004932:Esophageal and Gastric Varices / Q000150:complications*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D016558:Hemostasis, Endoscopic; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D015911:Sclerotherapy; D000077585:Terlipressin; D014014:Tissue Adhesives / Q000008:administration & dosage; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D003487:Cyanoacrylates; D005765:Gastrointestinal Agents; D014014:Tissue Adhesives; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin; D015282:Octreotide